SIRS Therapeutics

What SIRS Therapeutics does

SIRS Therapeutics GmbH is a development-stage biopharmaceutical company founded in 2018 and headquartered in Munich, Germany. It is focused on developing FX06, a fibrin-derived peptide therapeutic candidate, for the treatment of diseases related to vascular leakage, with an initial clinical indication in Acute Respiratory Distress Syndrome (ARDS) in patients with underlying COVID-19 infection. FX06 is being advanced in collaboration with F4 Pharma — the originator of the compound, from which SIRS Therapeutics acquired development rights — and through an exploratory partnership with Partner Therapeutics evaluating biodefense applications.

The company's differentiation rests on a mechanism-based approach that targets fibrin-breakdown-related vascular permeability rather than viral replication or broad anti-inflammatory pathways, positioning it as a complementary or alternative therapeutic for severe respiratory complications. As of the available data, SIRS Therapeutics holds no commercialized products, discloses no pricing, and operates with a 1-10 employee footprint. Its sole disclosed funding round was led by Wellington Partners in April 2020, with the round size undisclosed.

The business model is pre-commercial: SIRS Therapeutics is structured to advance FX06 through clinical and regulatory milestones, with no current distribution, sales, or marketing infrastructure. End customers, once approved, would be hospital systems treating critically ill ARDS patients, accessed via pharmaceutical supply chains and hospital procurement. The company's visibility is currently driven by scientific publication and partnership announcements rather than commercial GTM activity.

Name

SIRS Therapeutics

Legal name

SIRS Therapeutics GmbH

Website

https://sirs-therapeutics.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

SIRS Therapeutics GmbH is a Munich-based, development-stage biopharmaceutical company developing FX06, a fibrin-derived peptide therapeutic candidate targeting vascular leakage, with an initial indication in ARDS for severe COVID-19 patients, in collaboration with F4 Pharma and Partner Therapeutics.

Ownership category

akta.pro rank

Headquarters

HQ city

Munich

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Marketing channels1 record

Core offering

SIRS Therapeutics is a development-stage biopharmaceutical company developing FX06, a fibrin-derived peptide therapeutic candidate for the treatment of diseases related to vascular leakage. The lead indication is Acute Respiratory Distress Syndrome (ARDS) in patients with underlying COVID-19 infection, with additional exploratory potential in biodefense applications. The asset was originally developed by F4 Pharma and rights were acquired by SIRS Therapeutics for further clinical development.

Product overview

SIRS Therapeutics is a development-stage biopharmaceutical company developing a single product candidate, FX06, a fibrin-derived peptide. The company is focused on developing FX06 for the treatment of vascular leakage diseases, with initial clinical focus on ARDS in COVID-19 patients. The company operates in collaboration with F4 Pharma and has partnered with Partner Therapeutics for biodefense applications.

Differentiator

Problem solved

Functional benefit

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core and minor.

• F4 PharmacoreStrategic or Co-development PartnerF4 Pharma is collaborating with SIRS Therapeutics on the development of FX06. The partnership involves joint development efforts for the fibrin-derived peptide therapeutic candidate for ARDS treatment. FX06 was originally developed by F4 Pharma, and SIRS Therapeutics acquired rights for further development.
• Partner TherapeuticsminorStrategic or Co-development PartnerPartner Therapeutics announced a partnership with SIRS Therapeutics and F4 Pharma to explore potential uses for FX06 in biodefense applications. This is an exploratory collaboration to evaluate the therapeutic's potential beyond COVID-19, specifically for biodefense scenarios.

Recent moves4 records

Expansion highlights3 records

Emerging players

• Athersys: Athersys developed MultiStem cell therapy for ARDS and other critical-care inflammatory conditions, placing it in the same therapeutic area as SIRS Therapeutics. It is comparable as an early-stage company targeting ARDS via a distinct biological mechanism, making it a useful proxy for clinical and regulatory risk in this indication.
• BioCardia: BioCardia is a development-stage biopharma developing cell and biologic therapies for cardiac and pulmonary inflammatory conditions, including ARDS-adjacent indications. It is comparable to SIRS as a small clinical-stage company pursuing critical-care indications with a single lead asset and limited headcount.
• Pluristem Therapeutics: Pluristem developed PLX cell therapies for ARDS and other acute inflammatory conditions. It is comparable to SIRS as a development-stage biopharma pursuing ARDS with a non-conventional biologic modality, facing similar clinical, capital, and indication-pivot risks.
• Cartesian Therapeutics: Cartesian Therapeutics is a development-stage biopharma developing RNA-engineered cell therapies, including programs targeting acute respiratory and inflammatory conditions. It is comparable to SIRS as a small, modality-focused biotech tackling high-unmet-need critical-care indications with platform technology.

Broad incumbents

• Eli Lilly: Eli Lilly is a global biopharmaceutical incumbent with COVID-19 neutralizing antibodies (e.g., bebtelovimab-era programs) and broader inflammation/immunology pipelines. It is comparable to SIRS as a large established player whose COVID-19 and inflammation programs set the commercial and pricing context for a niche ARDS entrant.
• Roche: Roche is a global biopharmaceutical incumbent with a major COVID-19 antibody (Actemra/RoActemra) franchise and ongoing respiratory inflammation programs. It is comparable to SIRS as the dominant established player in ARDS/COVID-19 critical-care therapeutics that defines the competitive bar FX06 would have to clear.
• Boehringer Ingelheim: Boehringer Ingelheim is a large German-headquartered pharmaceutical company with a substantial respiratory and critical-care franchise, including work in ARDS and pulmonary fibrosis. It is comparable to SIRS as a potential acquirer/partner profile and as a benchmark for the broader respiratory biopharma landscape in which FX06 would compete.
• AstraZeneca (Alexion): AstraZeneca, via Alexion, is a global biopharmaceutical incumbent with deep experience in complement and vascular biology therapeutics for rare and acute conditions. It is comparable to SIRS as a potential strategic acquirer/partner for a vascular-leakage platform and as the closest large-pharma analog in mechanism-relevant biology.

Direct peers

• F4 Pharma: F4 Pharma is the original developer of FX06 and SIRS Therapeutics' core co-development partner. It is directly comparable because it works on the same fibrin-derived peptide technology targeting vascular leakage in critical-care indications, making it the closest functional peer despite the partnership relationship.
• Partner Therapeutics: Partner Therapeutics is a development-stage biopharmaceutical company focused on biodefense and critical-care therapeutics, and is a strategic partner of SIRS for FX06 biodefense applications. It is directly comparable because it pursues similar hospital/critical-care indications and operates with a similar development-stage, partnership-driven model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/sirs-therapeutics

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SIRS Therapeutics